<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17493" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amyloid Beta Peptide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rukmangadachar</surname>
            <given-names>Lokesh A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bollu</surname>
            <given-names>Pradeep C.</given-names>
          </name>
          <aff>University of Missouri</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lokesh Rukmangadachar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradeep Bollu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17493.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The amyloid-beta peptide appears to play a central role in the pathology of Alzheimer disease. Sporadic&#x000a0;Alzheimer disease&#x000a0;is the most common cause of dementia, with an estimated 50% to 56% cases in autopsy and clinical series. The disease starts insidiously, with age being the principal risk factor. Symptoms typically begin with memory deficits, progressing to other cognitive domains with death, usually in 10 years from diagnosis. A subset of&#x000a0;Alzheimer disease called familial&#x000a0;Alzheimer disease&#x000a0;accounts for 2% to 3% of&#x000a0;Alzheimer disease&#x000a0;cases. It tends to occur early in life, before age 60, as opposed to sporadic&#x000a0;Alzheimer disease, the incidence of which increases with age.<xref ref-type="bibr" rid="article-17493.r1">[1]</xref><xref ref-type="bibr" rid="article-17493.r2">[2]</xref><xref ref-type="bibr" rid="article-17493.r3">[3]</xref></p>
      </sec>
      <sec id="article-17493.s2" sec-type="Clinical Pathology">
        <title>Clinical Pathology</title>
        <p>The two hallmarks of the&#x000a0;Alzheimer disease&#x000a0;pathology are 1) extracellular plaque deposits of the amyloid beta peptide and 2) flame-shaped neurofibrillary tangles of the microtubule-binding protein tau. The production and deposition of the amyloid beta peptide appear to play a central role in the pathogenesis of&#x000a0;Alzheimer disease&#x000a0;and form the basis of the amyloid cascade hypothesis.</p>
        <p>Amyloid plaques are easily visible on routine hematoxylin and eosin (H and E) staining. These are extracellular and can be stained with special amyloid stains like Thioflavin-S or Congo Red. Under polarized light, they show characteristic apple-green birefringence typical for an amyloid protein.</p>
      </sec>
      <sec id="article-17493.s3" sec-type="Biochemical and Genetic Pathology">
        <title>Biochemical and Genetic Pathology</title>
        <p>Amyloid beta peptide is a 42-amino acid peptide and derives from the precursor protein, amyloid beta precursor protein (APP). The amyloid beta precursor protein&#x000a0;is a transmembrane glycoprotein that spans the membrane once. The gene for&#x000a0;amyloid beta precursor protein&#x000a0;is on chromosome 21.&#x000a0;Amyloid beta precursor protein&#x000a0;is cleaved by beta-secretase, and gamma secretase to release amyloid beta peptide containing 40 or 42 amino acids, denoted as <italic toggle="yes">Ab 1-40</italic> or <italic toggle="yes">Ab1-42, </italic>respectively. Beta secretase act on&#x000a0;amyloid beta precursor proteins&#x000a0;to produce the N terminal and gamma secretase produce the C terminal of the peptide. The peptide <italic toggle="yes">Ab 1-42</italic>, which is the main pathogenic peptide, is highly hydrophobic and tends to aggregate into oligomers and fibrils. The hydrophobic amino acids confer the hydrophobicity in the C terminal of the peptide. These fibrils then arrange in a beta-pleated sheet and form the amyloid plaques seen on conventional H and E staining or amyloid specific staining. Recent research suggests that the oligomers rather than the amyloid plaques are neurotoxic and may major play a role in pathogenesis.<xref ref-type="bibr" rid="article-17493.r4">[4]</xref><xref ref-type="bibr" rid="article-17493.r5">[5]</xref></p>
        <p>Several clinical and genetic observations support the amyloid cascade hypothesis. One of the initial observations of early-onset Alzheimer disease identified a genetic link to the disease. Patients with Down syndrome have an extra copy of chromosome 21 and, by inference, have excess&#x000a0;amyloid beta precursor protein&#x000a0;production. Most patients with Down syndrome have amyloid plaques in their brains by age 30 and clinically develop Alzheimer disease dementia in their 40s, suggesting a role for excess&#x000a0;amyloid beta precursor protein&#x000a0;or its processing in&#x000a0;Alzheimer disease. Mutations in the amyloid beta precursor protein&#x000a0;gene itself, one of the first studied in familial&#x000a0;Alzheimer disease,&#x000a0;account for 10% to 15% of familial&#x000a0;Alzheimer disease. Another mutation in the catalytic subunits of the gamma-secretase complex, the enzyme involved in processing&#x000a0;amyloid beta precursor protein&#x000a0;to an amyloid beta peptide, also causes familial&#x000a0;Alzheimer disease. Presenilin 1 and 2 are the subunits of the enzyme gamma secretase complex. Mutation in Presenilin 1 gene is the commonest cause of familial&#x000a0;Alzheimer disease. The gene for Presenilin 1 is located on chromosome 14 and accounts for up to 80% of cases of familial&#x000a0;Alzheimer disease. Researchers think that this mutation causes excess production of <italic toggle="yes">Ab 1-42</italic> as opposed to <italic toggle="yes">Ab 1-40</italic>. The gene for Presenilin 2 is on chromosome 1.</p>
        <p>Another well-established and supporting genetic risk factor for the amyloid cascade hypothesis is Apolipoprotein E (<italic toggle="yes">ApoE</italic>) polymorphism. There are three isoforms of the protein in the population encoded by the gene for <italic toggle="yes">ApoE</italic>; these are <italic toggle="yes">ApoE2</italic>, <italic toggle="yes">ApoE3</italic>, and <italic toggle="yes">ApoE4</italic>. Carriers with polymorphism ApoE4 have a higher risk of sporadic&#x000a0;Alzheimer disease&#x000a0;as compared to the general population. The risk is also higher in those with homozygous <italic toggle="yes">ApoE4</italic> as compared to heterozygous <italic toggle="yes">ApoE4</italic> suggesting a dose-dependent risk. Studies have shown a robust correlation with <italic toggle="yes">ApoE4</italic> gene carrier status and amyloid plaque burden in both patients with&#x000a0;Alzheimer disease&#x000a0;and cognitively normal individuals. Among the many functions, <italic toggle="yes">ApoE</italic> acts as a chaperone involved in the clearance of amyloid plaques, and the <italic toggle="yes">ApoE4</italic> isoform appears to be a poor chaperone promoting amyloid beta deposition.<xref ref-type="bibr" rid="article-17493.r6">[6]</xref><xref ref-type="bibr" rid="article-17493.r7">[7]</xref><xref ref-type="bibr" rid="article-17493.r8">[8]</xref></p>
      </sec>
      <sec id="article-17493.s4" sec-type="Mechanisms">
        <title>Mechanisms</title>
        <p>The normal function of the amyloid beta peptide is not known. Mechanisms exist in the human brain to degrade the amyloid beta peptide. Despite this, a faction of this may remain in the brain, which is transported out of the human brain across the blood-brain barrier. An imbalance in these pathways appears to lead to the accumulation of the peptide. Recent research suggests that amyloid beta oligomers are more important in the pathogenesis than the plaques. These oligomers are thought to induce synaptic dysfunction, disrupt neural connectivity, and neuronal death.<xref ref-type="bibr" rid="article-17493.r9">[9]</xref><xref ref-type="bibr" rid="article-17493.r10">[10]</xref></p>
      </sec>
      <sec id="article-17493.s5" sec-type="Clinicopathologic Correlations">
        <title>Clinicopathologic Correlations</title>
        <p>Although amyloid beta plaques are pathognomonic of Alzheimer disease pathology, there is no strong correlation of amyloid beta plaque burden, spatiotemporal distribution, and&#x000a0;Alzheimer disease&#x000a0;severity. It is possible, however, that the total amyloid plaque burden increases as&#x000a0;Alzheimer disease&#x000a0;progresses. In contrast, the spatiotemporal distribution of tau neurofibrillary tangles follows a predictable pattern, with neurofibrillary tangles seen in the entorhinal cortex and hippocampus and gradually spreading to involve other areas, with primary motor, sensory and visual areas involved in the last stages of&#x000a0;Alzheimer disease.</p>
      </sec>
      <sec id="article-17493.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Amyloid plaque burden and spatial distribution of the plaques are now visible on imaging. A radiotracer called Pittsburgh Compound B is FDA approved for use in PET scan for the diagnosis of&#x000a0;Alzheimer disease. This molecule preferentially targets and binds to amyloid beta plaques with high affinity and specificity and can estimate the plaque burden and distribution of&#x000a0;Alzheimer disease. This imaging is now in use in almost all clinical trials of&#x000a0;Alzheimer disease.</p>
        <p>Free amyloid peptide levels are measurable in cerebrospinal fluid (CSF) and plasma. Low levels of amyloid beta, perhaps an indicator of low clearance from the brain, and abnormally high tau protein in CSF serve as biomarkers of&#x000a0;Alzheimer disease&#x000a0;in clinical trials.</p>
        <p>
<bold>Amyloid Beta as Therapeutic Target</bold>
</p>
        <p>Several clinical trials using immunotherapy have attempted to decrease plaque burden as a mechanism to stop the progression of Alzheimer disease. However, most of these trials failed to meet the primary endpoint or were stopped due to safety concerns. Typically, vaccination against the amyloid beta or passive immunization with antibodies targeted against amyloid peptide was the attempted intervention. The failure of these therapies may argue against the central role of amyloid deposition in&#x000a0;Alzheimer disease. However, it is possible that the treatments were tested in the later stages of the disease rather than early in the disease process when the impact on disease modification could be higher. Alternatively, this approach does not address the tau protein pathway in the disease and hence could not affect disease progression.</p>
        <p>
<bold>Teaching Points</bold>
</p>
        <p>The amyloid precursor protein is processed to form an amyloid beta peptide. An imbalance in production and clearing of the peptide appears to lead to the formation of excess amyloid oligomers and amyloid plaques. The latter is the histopathological hallmarks of&#x000a0;Alzheimer disease.</p>
        <p>The gene for&#x000a0;amyloid precursor protein&#x000a0;is located on chromosome 21 and encodes a transmembrane protein. The amyloid precursor protein&#x000a0;is cleaved by beta-secretase and gamma-secretase to release the amyloid beta peptide. Genetic mutation of the&#x000a0;amyloid precursor protein&#x000a0;gene or the catalytic subunits of the gamma-secretase complex, for example, Presenilin 1 and Presenilin 2, cause familial&#x000a0;Alzheimer disease.</p>
        <p>Mutation in amyloid precursor protein was the first to be discovered, but a mutation in Presenilin 1 is the most common cause (up to 80%) of familial&#x000a0;Alzheimer disease.</p>
        <p>Familial Alzheimer disease characteristically presents with early-onset dementia, onset before age 60 years, and usually autosomal dominant inheritance pattern.</p>
        <p><italic toggle="yes">Apo E4</italic> carrier status confers a high risk for sporadic&#x000a0;Alzheimer disease. This risk is dose-dependent with homozygous status conferring higher risk.</p>
        <p>Low&#x000a0;CSF amyloid beta peptide and high CSF Tau peptides&#x000a0;are biomarkers in a clinical trial setting.</p>
        <p>Chemical compounds, for example, Pittsburgh Compound B, that bind the amyloid plaque, can be used as imaging biomarkers.</p>
      </sec>
      <sec id="article-17493.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17493&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17493">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17493/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17493">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17493.s8">
        <title>References</title>
        <ref id="article-17493.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honcharenko</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Juneja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roshan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maity</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gal&#x000e1;n-Acosta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Biverst&#x000e5;l</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hjorth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Str&#x000f6;mberg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Amyloid-&#x003b2; Peptide Targeting Peptidomimetics for Prevention of Neurotoxicity.</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>1462</fpage>
            <page-range>1462-1477</page-range>
            <pub-id pub-id-type="pmid">30673220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadiki</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>Idrissi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cioanca</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Trifan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hancianu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hritcu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Postu</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Tetraclinis articulata essential oil mitigates cognitive deficits and brain oxidative stress in an Alzheimer's disease amyloidosis model.</article-title>
            <source>Phytomedicine</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>56</volume>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">30668354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowalski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mulak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Brain-Gut-Microbiota Axis in Alzheimer's Disease.</article-title>
            <source>J Neurogastroenterol Motil</source>
            <year>2019</year>
            <month>Jan</month>
            <day>31</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-60</page-range>
            <pub-id pub-id-type="pmid">30646475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>JZA</given-names>
              </name>
              <name>
                <surname>Gleeson</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease.</article-title>
            <source>Biochim Biophys Acta Biomembr</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>1861</volume>
            <issue>4</issue>
            <fpage>697</fpage>
            <page-range>697-712</page-range>
            <pub-id pub-id-type="pmid">30639513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Tauopathy: A common mechanism for neurodegeneration and brain aging.</article-title>
            <source>Mech Ageing Dev</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>178</volume>
            <fpage>72</fpage>
            <page-range>72-79</page-range>
            <pub-id pub-id-type="pmid">30668956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panza</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lozupone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Imbimbo</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>A critical appraisal of amyloid-&#x003b2;-targeting therapies for Alzheimer&#x000a0;disease.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-88</page-range>
            <pub-id pub-id-type="pmid">30610216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gratuze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leyns</surname>
                <given-names>CEG</given-names>
              </name>
              <name>
                <surname>Holtzman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>New insights into the role of TREM2 in Alzheimer's disease.</article-title>
            <source>Mol Neurodegener</source>
            <year>2018</year>
            <month>Dec</month>
            <day>20</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">30572908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Souza</surname>
                <given-names>RMDCE</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>ICS</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>ABT</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>PHV</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>VRX</given-names>
              </name>
            </person-group>
            <article-title>Focused ultrasound and Alzheimer's disease A systematic review.</article-title>
            <source>Dement Neuropsychol</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-359</page-range>
            <pub-id pub-id-type="pmid">30546844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present).</article-title>
            <source>Curr Med Chem</source>
            <year>2019</year>
            <volume>26</volume>
            <issue>30</issue>
            <fpage>5684</fpage>
            <page-range>5684-5710</page-range>
            <pub-id pub-id-type="pmid">30501591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17493.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solana</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tarazona</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Solana</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease.</article-title>
            <source>Int J Alzheimers Dis</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>3128758</fpage>
            <pub-id pub-id-type="pmid">30515321</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
